glp 1 agonist heart disease GLP-1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Results of cardiovascular outcomes trials

Payment does not guarantee the writing or dispensing of a prescription

These interactions may be: Additive (combined effect equals the sum of individual effects)

Pharmacokinetic study Plasma agonist concentration after a single IP injection (24 nmol kg 1 ) was measured with an exendin-4 C-terminus-specific ELISA (Phoenix Pharmaceuticals), a peptide region that does not differ between agonists, hence equally detecting exendin-4 and exendin-phe1 (confirmed by analysis of known concentrations of each agonist)

doi: 10.1111/dom.12593 [DOI] [PubMed] [Google Scholar] 28

This study systematically analyzed 175 health outcomes in 2 million people using glucagon-like peptide-1 receptor agonists (GLP-1RAs) or other antihyperglycemics